Proteomic profiling of naïve multiple myeloma patient plasma cells identifies pathways associated with favourable response to bortezomib-based treatment regimens
Dominik Dytfeld, Shaun Rosebeck, Malathi Kandarpa, Anoop Mayampurath, Dattatreya Mellacheruvu, Mattina M Alonge, Lambert Ngoka, Jagoda Jasielec, Paul G Richardson, Samuel Volchenboum, Alexey I Nesvizhskii, Arun Sreekumar, Andrzej J Jakubowiak, Dominik Dytfeld, Shaun Rosebeck, Malathi Kandarpa, Anoop Mayampurath, Dattatreya Mellacheruvu, Mattina M Alonge, Lambert Ngoka, Jagoda Jasielec, Paul G Richardson, Samuel Volchenboum, Alexey I Nesvizhskii, Arun Sreekumar, Andrzej J Jakubowiak
Abstract
Toward our goal of personalized medicine, we comprehensively profiled pre-treatment malignant plasma cells from multiple myeloma patients and prospectively identified pathways predictive of favourable response to bortezomib-based treatment regimens. We utilized two complementary quantitative proteomics platforms to identify differentially-regulated proteins indicative of at least a very good partial response (VGPR) or complete response/near complete response (CR/nCR) to two treatment regimens containing either bortezomib, liposomal doxorubicin and dexamethasone (VDD), or lenalidomide, bortezomib and dexamethasone (RVD). Our results suggest enrichment of 'universal response' pathways that are common to both treatment regimens and are probable predictors of favourable response to bortezomib, including a subset of endoplasmic reticulum stress pathways. The data also implicate pathways unique to each regimen that may predict sensitivity to DNA-damaging agents, such as mitochondrial dysfunction, and immunomodulatory drugs, which was associated with acute phase response signalling. Overall, we identified patterns of tumour characteristics that may predict response to bortezomib-based regimens and their components. These results provide a rationale for further evaluation of the protein profiles identified herein for targeted selection of anti-myeloma therapy to increase the likelihood of improved treatment outcome of patients with newly-diagnosed myeloma.
Trial registration: ClinicalTrials.gov NCT00116961 NCT00378105.
Keywords: bortezomib; lenalidomide; multiple myeloma; proteomics.
© 2015 John Wiley & Sons Ltd.
Source: PubMed